

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vigonvita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

INSIDE INFORMATION

GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE IN RESPECT OF THE H SHARE FULL CIRCULATION OF THE COMPANY

This announcement is made by Vigonvita Life Sciences Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated November 27, 2025 and June 29, 2026 (the “**Announcements**”) in relation to the proposed implementation of the H Share Full Circulation by the Company and the receipt by the Company of the Filing Notice issued by the CSRC in respect of the H Share Full Circulation. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that the Company has received the listing approval granted by the Stock Exchange on July 3, 2026 for the listing of, and permission to deal in, the 100,220,667 H Shares, being the total number of Unlisted Shares to be converted and listed.

The Conversion and Listing will involve a total of 10 participating Shareholders of the Company (the “**Participating Shareholders**”), who collectively hold 100,220,667 Unlisted Shares. Upon completion of the Conversion and Listing, details of the Shares to be converted by the Participating Shareholders are as follows:

Name of Shareholder	Number of Unlisted Shares to be converted into H Shares (Shares)	Percentage of the total issued share capital of the Company upon completion of the Conversion and Listing
Shen Jingshan (沈敬山)	82,461,110	49.2018%
Jin Jie (金潔)	2,272,478	1.3559%
Tian Guanghui (田廣輝)	5,726,644	3.4169%
Ganzhou Yufei Shanshui Equity Investment Partnership Enterprise (Limited Partnership) (贛州 予飛杉水股權投資合夥企業(有限合夥))	4,174,758	2.4909%
Jiaxing Yuhan Equity Investment Partnership Enterprise (Limited Partnership) (嘉興譽瀚股權投 資合夥企業(有限合夥))	800,000	0.4773%
Qingdao Bei'an Industrial Investment Holding Co., Ltd. (青島北岸產業投資控股有限公司)	3,401,354	2.0295%
Fuzhou Xindui Investment Partnership Enterprise (Limited Partnership) (福州鑫兌投資合夥企業(有限 合夥))	688,379	0.4107%
Wang Zhiqiang (王志強)	198,841	0.1186%
Guo Ting (郭婷)	298,262	0.1780%
Yao Zheng (藥箏)	198,841	0.1186%
Total	100,220,667	59.7983%

The shareholding structures of the Company as at the date of this announcement and upon completion of the Conversion and Listing are set out below:

Type of Shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	Number of Shares (Shares)	Approximate percentage of the total number of issued Shares of the Company	Number of Shares (Shares)	Approximate percentage of the total number of issued Shares of the Company
Domestic Unlisted Shares	100,920,667	60.22%	700,000	0.42%
H Shares	66,677,133	39.78%	166,897,800	99.58%
Total	167,597,800	100 %	167,597,800	100 %

The Company will proceed to complete the procedures in connection with the conversion of the Unlisted Shares into H Shares. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements of the Inside Information Provisions and/or the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares of the Company.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, July 6, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.